Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Up 35.2% in July

Viracta Therapeutics, Inc. (NASDAQ:VIRX) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 974,800 shares, an increase of 35.2% from the June 30th total of 721,000 shares. Currently, 3.5% of the company’s stock are short sold. Based on an average daily volume of 91,500 shares, the short-interest ratio is presently 10.7 days.

Viracta Therapeutics Stock Performance

Shares of VIRX traded up $0.02 during trading hours on Monday, hitting $0.50. 46,934 shares of the company were exchanged, compared to its average volume of 102,468. Viracta Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $1.68. The firm’s fifty day moving average is $0.59 and its 200 day moving average is $0.73.

Viracta Therapeutics (NASDAQ:VIRX) last released its earnings results on Thursday, May 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.12. Sell-side analysts expect that Viracta Therapeutics will post -1.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on VIRX shares. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Viracta Therapeutics in a research note on Tuesday, April 16th. Oppenheimer dropped their price target on Viracta Therapeutics from $13.00 to $11.00 and set an “outperform” rating on the stock in a research note on Thursday, May 23rd.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.